Eli Lilly to sell half-price version of insulin injection
Drugmakers coming under pressure over rapid increases in prices of established medicines
Eli Lilly’s blockbuster insulin product Humalog. Photograph: AFP/Getty Images
Major drugmakers including Lilly, a leading producer of insulin, have come under fire from patients and law-makers over the rising cost of the life-saving medication used to treat diabetes.
Lilly’s generic insulin product would be called Insulin Lispro, it said, while Humalog, one of the company’s top-selling products with $3 billion in annual sales, will remain available for those wishing to access it through their existing insurance plans.
The move comes as the US government increases scrutiny into the pharmaceutical industry and rising costs of prescription drugs in the US, a top voter concern.
The cost of insulin for treating type 1 diabetes in the US has nearly doubled over a five-year period, Reuters reported in January.
Lilly said the list price for one vial of Insulin Lispro, which will be sold only in the US, would be $137.35. For uninsured patients or those with high-deductible insurance plans, Insulin Lispro can make insulin more affordable, the Indianapolis-based drugmaker added.
Lilly said it had spoken to various “stakeholders” about the price of insulin, including diabetes patients, doctors, advocacy groups, wholesalers and law-makers.
“For people with diabetes a lower-priced insulin can serve as a bridge that addresses gaps in the system until a more sustainable model is achieved,” Lilly chief executive David Ricks said in a statement.
Two US senators last month launched an investigation into rising insulin prices, writing to Lilly and two other leading manufacturers, asking them why the cost of the nearly 100-year-old medication had rapidly risen.
The price of Humalog, for instance, rose from $35 to $234 per dose between 2001 and 2015, a 585 per cent increase, the senators said.
Lilly has in the past called insulin a highly-rebated product. Drugmakers often argue they have to keep prices high because of the rebates they must pay to pharmacy benefit managers and health insurers to get products on their lists of covered drugs.
The US government in January proposed a rule to end the industry-wide system of rebates. Lilly has previously voiced its support for the proposal and on Monday it affirmed that stance.
“The significant rebates we pay on insulins do not directly benefit all patients,” Mr Ricks said. “This needs to change.” – Reuters